Logo

American Heart Association

  2
  0


Final ID: MDP612

Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights from the National Cardiovascular Data Registry (NCDR) CathPCI Registry

Abstract Body (Do not enter title and authors here): Background: Although transcatheter aortic valve replacement (TAVR) devices can impair coronary access, there are limited real-world data on rates of percutaneous coronary intervention (PCI) and PCI outcomes in post-TAVR patients.
Research Question: How often do patients who undergo TAVR develop coronary events, and do they have different procedural characteristics or rates of adverse events when undergoing PCI compared to patients without a TAVR?
Methods: We used CMS claims data for the Medicare fee-for-service population to evaluate the incidence of PCI after TAVR between 2011-2017. Then, using data from the NCDR CathPCI Registry linked with Medicare claims, we compared procedural characteristics and PCI outcomes between patients with a history of TAVR vs. propensity-matched patients who did not have a history of TAVR.
Results: Of the 52,780 Medicare fee-for-service patients who underwent TAVR between 2011-2017, the incidence of acute myocardial infarction (AMI) was 10.6% and of PCI was 5.4% at five years. Among those patients, 5.6% had a PCI in the three months preceding their TAVR. After propensity-score matching, the procedural success rates for PCI were similar between patients with vs. without a history of TAVR. However, in the propensity-matched comparison, PCI in post-TAVR patients required greater fluoroscopic time (21.9 vs 17.7 mins, p<0.001) and was associated with a greater incidence of post-procedural stroke (0.8% vs 0.4%, p=0.02) and bleeding (5.1% vs 2.9%, p < 0.001). At three-year follow-up post-PCI, there were no differences in the rates of AMI between patients with vs. without a history of TAVR (HR: 1.22, 95% C.I.: 0.97, 1.54, p=0.08). However, patients with prior TAVR were more likely to have repeat PCI in the three years following their index procedure (HR: 1.38, 95% C.I.: 1.12, 1.73, p=0.003).
Conclusion: Among Medicare fee-for-service patients, one in 20 patients undergoing TAVR subsequently underwent PCI within 5 years. Although the rates of procedural success were similar, patients with a history of TAVR who underwent PCI had longer fluoroscopic times, more frequent in-hospital adverse events, and a higher likelihood of a repeat PCI compared with matched patients without a history of TAVR.
  • Lalani, Christina  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Kolte, Dhaval  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Cohen, David  ( Cardiovascular Research Foundation , New York , New York , United States )
  • Yeh, Robert  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Sharma, Ravi  ( Norton Healthcare , Louisville , Kentucky , United States )
  • Sevilla-cazes, Jonathan  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Kennedy, Kevin  ( St. Luke's Hospital , Kansas City , Missouri , United States )
  • Butala, Neel  ( University of Colorado , Aurora , Colorado , United States )
  • Secemsky, Eric  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Pinto, Duane  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Poulin, Marie-france  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Laham, Roger  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Author Disclosures:
    Christina Lalani: DO NOT have relevant financial relationships | Dhaval Kolte: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH/NHLBI:Active (exists now) ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) | David Cohen: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Research Funding (PI or named investigator):IRhythm:Past (completed) ; Research Funding (PI or named investigator):Zoll Medical:Active (exists now) ; Research Funding (PI or named investigator):Corvia Medical:Active (exists now) ; Research Funding (PI or named investigator):Philips:Active (exists now) ; Research Funding (PI or named investigator):CathWorks:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Active (exists now) ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) | Robert Yeh: DO have relevant financial relationships ; Consultant:abbott vascular :Active (exists now) ; Consultant:shiockwavw:Active (exists now) ; Consultant:cathworks:Active (exists now) ; Consultant:medronic:Active (exists now) ; Consultant:Boston scientific :Active (exists now) | Ravi Sharma: No Answer | Jonathan Sevilla-Cazes: No Answer | kevin kennedy: No Answer | Neel Butala: DO have relevant financial relationships ; Consultant:Boston Scientific:Past (completed) ; Ownership Interest:CatchBio:Active (exists now) ; Consultant:CatchBio:Active (exists now) ; Ownership Interest:HiLabs:Active (exists now) ; Consultant:HiLabs:Active (exists now) ; Consultant:Shockwave Medical:Past (completed) | Eric Secemsky: DO have relevant financial relationships ; Consultant:Abbott/CSI, BD, BMS, Boston Scientific, Cagent, Conavi, Cook, Cordis, Endovascular Engineering, Gore, InfraRedx, Medtronic, Philips, RapidAI, Rampart, Shockwave, Terumo, Thrombolex, VentureMed, Zoll:Active (exists now) | Duane Pinto: DO have relevant financial relationships ; Executive Role:Jenavalve:Active (exists now) ; Consultant:AriaCV:Active (exists now) ; Consultant:Magenta:Active (exists now) ; Consultant:Abbott:Active (exists now) | Marie-France Poulin: No Answer | Roger Laham: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

More abstracts on this topic:
Accumulation of Epicardial Adipose Tissue as a Marker of Diastolic Dysfunction in Patients With Preserved Left Ventricular Ejection Fraction Undergoing Coronary Computed Tomography Angiograph

Ishikawa Hirotoshi, Kasayuki Noriaki, Fukuda Daiju, Otsuka Kenichiro, Sugiyama Takatoshi, Yamaura Hiroki, Hojo Kana, Kawa Yoshinori, Shintani Ako, Ito Asahiro, Yamazaki Takanori

ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis.

Nitsche Christian, Muller Steven, Gama Francisco, Hamdan Ashraf, Kelion Andrew, Schuster Andreas, Glaveckaite Sigita, Porcari Aldostefano, Autherith Maximilian, Hauptmann Laurenz, Halavina Kseniya, Dobner Stephan, Scully Paul, Moon James, Mascherbauer Julia, Biagini Elena, Stortecky Stefan, Maurer Matthew, Treibel Thomas, Rosenblum Hannah, Patel Kush, Longhi Simone, Yilmaz Ali, Merlo Marco, Papathanasiou Maria, Griffin Jan

More abstracts from these authors:
Cannabis Legalization and Cardiovascular Hospitalizations: A Nationwide Difference-in-Differences Analysis

Slavin Samuel, Mahar Amy, Secemsky Eric, Yeh Robert, Mittleman Murray

Changes in Contrast Volume among Patients Undergoing Percutaneous Coronary Intervention: a Report from NCDR CathPCI registry

Ikemura Nobuhiro, Chan Paul, Cohen David, Kennedy Kevin, Uzendu Anezi, Kohsaka Shun, Spertus John

You have to be authorized to contact abstract author. Please, Login
Not Available